Anistreplase is a thrombolytic drug.[1][2][3]
Anistreplase has been developed by Beecham as Eminase. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC)
[edit] Mechanism
It converts plasminogen to plasmin, which in turn degrades fibrin (blood clots) to fibrin split products.
[edit] References
| Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01) | | | Antiplatelet drugs | | | | Anticoagulants | | | | | Factor Xa inhibitors (with some II inhibition) | | | low molecular weight heparin (Bemiparin, Certoparin, Dalteparin, Enoxaparin, Nadroparin, Parnaparin, Reviparin, Tinzaparin) oligosaccharides (Fondaparinux, Idraparinux) heparinoid ( Danaparoid, Sulodexide, Dermatan sulfate) | | | | | | | | | | | | Other | | | | Thrombolytic drugs/
fibrinolytics | | | | Non-medicinal | | | | | |
